



Nyxoah to Host Investor Day in New York on July 8, 2026

Leadership team and Board will discuss the U.S. commercial execution, growth strategy and key priorities

Mont-Saint-Guibert, Belgium – June 23, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced that it will host an Investor and Analyst Day on Wednesday, July 8, 2026, in New York. The event will be held at the offices of Bank of America and will run from 10:00 AM to 12:30 PM ET (16:00 to 18:30 CET).

The event will be webcast live for those unable to attend in person, with a replay available shortly afterwards. Participants joining via the webcast will be able to ask questions during the event.

Event details

- Date: Wednesday, July 8, 2026
- Time: 10:00 AM to 12:30 PM ET (16:00 to 18:30 CET)
- Location: Bank of America Tower at One Bryant Park, 1111 Avenue of the Americas, New York, NY
- Registration and webcast access: the link will be posted in the [Events section of Nyxoah’s investor website](#) or by contacting IR@nyxoah.com.

Agenda highlights

Nyxoah’s leadership team, Board members, and external experts will discuss the Company’s commercial execution, growth strategy, and key priorities, including:

- Genio U.S. launch momentum:
 - Review of second-quarter commercial key performance indicators
 - Physicians’ perspective on real-world U.S. experience with Genio
 - Market dynamics shaping Obstructive Sleep Apnea
- Reimbursement: Assessment of the U.S. reimbursement landscape, presented together with JD Lymon Group, an independent market access and reimbursement consulting firm.
- Path to profitability: Company’s framework for disciplined growth, capital efficiency and operating leverage.

Featured participants

Scheduled participants include Nyxoah’s leadership team and board, joined by external clinical and reimbursement experts:



- Robert Taub, Chairman of the Board; Olivier Taelman, Chief Executive Officer; and the Nyxoah executive team
- Andrew T. Huang, MD, FACS – Pasha Snoring & Sinus Center (Houston, TX); former Director of Sleep Surgery, Baylor College of Medicine
- Vikas Jain, MD, FAASM, FAAFP, CPE – Dream Center for Sleep & Circadian Science (Frisco, TX)
- JD Lymon Group

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah's lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's most common sleep-disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and Nasdaq in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE Mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit <http://www.nyxoah.com/>.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or management's current expectations regarding the Company's Investor Day; the Genio system; the potential advantages of the Genio system; the Company's commercialization strategy and growth in the U.S. market; reimbursement; and the Company's path to profitability. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on March 26, 2026 and



subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoaah

John Landry, CFO

IR@nyxoah.com

Rémi Renard, Head of Investor Relations & Corporate Communication

IR@nyxoah.com